Biosimilars Market Set to Reshape Access to Biologic Medicines

The global biosimilars market is expanding rapidly as healthcare systems seek cost-effective alternatives to biologic medicines and improve access to advanced therapies. Growing adoption of biosimilars across therapeutic areas, increasing regulatory support, and the expiration of patents for major biologic drugs are creating new opportunities for manufacturers. Rising healthcare expenditure and the need to reduce treatment costs are also encouraging healthcare providers and patients to consider biosimilar therapies.

The global biosimilars market size was valued at USD 37.73 billion in 2025 and is projected to grow from USD 42.80 billion in 2026 to USD 117.28 billion by 2034, registering a CAGR of 13.43% during the forecast period from 2026 to 2034. Europe dominated the biosimilars market with a market share of 38.5% in 2025, supported by established regulatory frameworks, early biosimilar adoption, and strong healthcare infrastructure.

For detailed market insights, growth forecasts, and competitive analysis, visit: https://straitsresearch.com/report/biosimilars-market

Market Drivers

Growing demand for cost-effective biologic therapies

The high cost of many biologic medicines is increasing demand for more affordable treatment alternatives. Biosimilars can provide additional treatment options while supporting healthcare systems in managing pharmaceutical expenditure. Growing pressure to improve access to biologic therapies is therefore contributing to biosimilar adoption across multiple therapeutic areas.

Increasing patent expirations of biologic drugs

The expiration of patents and exclusivity periods for established biologic medicines is creating opportunities for biosimilar manufacturers. As more biologic products become eligible for biosimilar competition, pharmaceutical companies are expanding their development pipelines and manufacturing capabilities. Increasing availability of approved biosimilars is supporting market expansion.

Expanding regulatory support and adoption

Regulatory agencies in major pharmaceutical markets have established pathways for the development and approval of biosimilars. Clearer regulatory frameworks are helping manufacturers navigate product development while improving confidence among healthcare providers. Increasing clinical experience and regulatory approvals are further supporting broader adoption of biosimilar medicines.

Market Challenges

Complex development and manufacturing processes

Biosimilars require sophisticated biological manufacturing processes, analytical characterization, quality controls, and clinical evaluation. Developing products that demonstrate similarity to reference biologics can require significant technical expertise and investment. Manufacturing complexity can create barriers for smaller pharmaceutical companies entering the market.

Limited awareness among healthcare stakeholders

Understanding and acceptance of biosimilars can vary among physicians, patients, and other healthcare stakeholders. Concerns about interchangeability, efficacy, safety, and treatment outcomes may influence prescribing decisions in some markets. Continued education and real-world evidence can help healthcare professionals make informed decisions about biosimilar use.

Pricing and market access challenges

Although biosimilars can increase competition and potentially reduce treatment costs, manufacturers face pricing pressure as multiple products enter the same therapeutic market. Reimbursement policies, procurement practices, substitution rules, and market access requirements can also influence commercial performance. Companies must balance competitive pricing with the costs associated with development and manufacturing.

Market Segmentation

By product

The biosimilars market can be segmented into monoclonal antibodies, recombinant proteins, insulin, and other biosimilar products. Monoclonal antibodies represent an important category because of their widespread use in oncology, autoimmune disorders, and other chronic conditions, while expanding biosimilar pipelines are increasing product diversity.

By indication

Based on indication, biosimilars are used across oncology, autoimmune diseases, diabetes, hematology, and other therapeutic areas. Increasing adoption in oncology and chronic disease management is supporting demand as healthcare providers seek effective and economically accessible biologic treatment options.

By distribution channel

Based on distribution channel, the market includes hospital pharmacies, retail pharmacies, specialty pharmacies, and other channels. Hospital pharmacies represent an important distribution route for biosimilars used in specialized and hospital-based treatments, while specialty pharmacy networks support access to complex biologic therapies.

By region

Geographically, the biosimilars market covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Europe accounted for the largest market share in 2025, while increasing regulatory support, healthcare expenditure, and biosimilar adoption are supporting market development across other regions.

Regional Insights

North America

North America represents a significant biosimilars market, supported by increasing adoption of biosimilar therapies, advanced healthcare infrastructure, and growing efforts to manage pharmaceutical spending. The expansion of approved biosimilar products and increasing awareness among healthcare providers are contributing to regional market development.

Europe

Europe dominated the biosimilars market with a 38.5% share in 2025. The region benefits from established biosimilar regulatory frameworks, early market adoption, strong healthcare systems, and extensive clinical experience with biosimilar therapies. Increasing competition among biologic manufacturers is also supporting broader availability of biosimilar medicines.

Asia Pacific

The Asia Pacific market is supported by rising healthcare expenditure, increasing demand for affordable biologic treatments, expanding pharmaceutical manufacturing capabilities, and growing awareness of biosimilars. Countries across the region are strengthening their biopharmaceutical industries, creating opportunities for biosimilar development and commercialization.

Key Players Analysis

The major players in the biosimilars market include Amgen Inc., Biocon Biologics Ltd., Celltrion Inc., Sandoz Group AG, and Pfizer Inc.

• Amgen Inc.
• Biocon Biologics Ltd.
• Celltrion Inc.
• Sandoz Group AG
• Pfizer Inc.

Conclusion

The biosimilars market is expanding rapidly as healthcare systems seek affordable access to biologic therapies and pharmaceutical companies increase biosimilar development. The market is projected to grow from USD 42.80 billion in 2026 to USD 117.28 billion by 2034 at a CAGR of 13.43%. Patent expirations, regulatory support, increasing healthcare expenditure, and growing acceptance of biosimilar treatments are expected to remain key factors supporting market growth throughout the forecast period.

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: [email protected]

Tel: +1 646 905 0080 (U.S.)

Tel: +44 203 695 0070 (U.K.)